Immunome (IMNM) risk factors, FY2024 10-K

Risks Related to Our Business

1. 01We are a biopharmaceutical company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability
2. 02We have a limited operating history, which may make it difficult to evaluate our drug development capabilities and predict our future performance
3. 03We will need to raise substantial additional funds to advance development of our product candidates and our ADC platform, and we cannot guarantee that we will have sufficient funds available in the future to develop and commercialize any of our product candidates

Risks Related to Our Discovery, Development and Regulatory Approval of Programs and Product Candidates

1. 04We may be unable to advance any of our product candidates into and through clinical development, obtain regulatory approvals and ultimately commercialize them, or we could experience significant delays in doing so
2. 05We may not be successful in our efforts to use and expand our ADC platform to build and progress a pipeline
3. 06We may pursue particular programs or product candidates over others; these decisions may prove to be wrong and may adversely impact our business
4. 07We may fail to realize the business benefits anticipated as a result of completed or future strategic transactions
5. 08As a targeted radioligand therapy, our IM-3050 program may face additional and potentially unpredictable challenges
6. 09Clinical trials are expensive, time-consuming and difficult to design and implement
7. 10If we encounter difficulties enrolling participants in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected
8. 11We may experience delays in completion of our clinical trials based on study design
9. 12We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us. If their product candidates are shown to be safer or more effective than ours, then our commercial opportunity will be reduced or eliminated
10. 13The market may not be receptive to our product candidates, and we may not generate any revenue from their sale, partnering or licensing
11. 14If the market opportunities for our product candidates are smaller than we believe they are, our future product revenues may be adversely affected, and our business may suffer
12. 15If we or others identify undesirable side effects caused by any of our current or future product candidates undergoing clinical trials, our ability to market and derive revenue from the product candidate could be compromised
13. 16A Fast Track Designation from the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive regulatory approval
14. 17We may fail to obtain orphan drug designations from the FDA for our product candidates, and even if we obtain such designations, we may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity
15. 18Additional regulatory burdens and other risks and uncertainties in foreign markets may limit our growth
16. 19Our business entails a significant risk of product liability, which may not be sufficiently covered by our insurance
17. 20We have obtained rights to use human samples in furtherance of our research and development. However, if we failed to obtain appropriate permission to use these samples or exceed the scope of the permissions given, our programs could be adversely affected

Risks Related to Government Regulation

1. 21Health care legislative reform measures may have a material adverse effect on our business and results of operations
2. 22If we or our existing or potential future partners, manufacturers or other service providers fail to comply with health care laws and regulations, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our products and may harm our reputation
3. 23Any programs or product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated
4. 24Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements
5. 25Even if we are able to commercialize any program or product candidate, the program and product candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business
6. 26We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal or civil liability and harm our business

Risks Related to Strategic Transactions, Manufacturing, Commercialization and Reliance on Third Parties

1. 27Because we rely on third parties for manufacturing, supply and testing, some of which may be sole source vendors, for preclinical and clinical development materials and commercial supplies, our supply may become limited or interrupted or may not be of satisfactory quantity or quality
2. 28We may be unable to successfully scale manufacturing in sufficient quality and quantity, which would delay or prevent us from completing our development and commercialization efforts, if any
3. 29Our significant reliance on third-party vendors could impair our ability to implement our business plan
4. 30In the ordinary course of business, we, our collaborators, our vendors, and other third parties with whom we work may process proprietary, confidential, and sensitive data, including our clinical trial data or personal information, or collectively, sensitive data
5. 31Remote work has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers and devices outside our premises or network, including working at home, while in transit and in public locations
6. 32Further, some of our contracts do not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations
7. 33Our current laboratory operations are concentrated in one location, and we and the third parties upon whom we depend may be adversely affected by natural or other disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster

Risks Related to Our Intellectual Property

1. 34It is difficult and costly to protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection
2. 35Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
3. 36Patent terms may not be able to protect our competitive position for an adequate period of time with respect to our current or future targeted therapeutics
4. 37Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our current or any future targeted therapeutics
5. 38We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business
6. 39In order to protect our competitive position around our future products, we may become involved in lawsuits to enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful and which may result in our patents being found invalid or unenforceable
7. 40A third party may hold intellectual property, including patent rights, that are important or necessary to the development of our targeted therapeutics. It may be necessary for us to use the patented or proprietary technology of one or more third parties to commercialize our current and future targeted therapeutics
8. 41If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected targeted therapeutics
9. 42We are reliant upon in-licenses to certain patent rights and proprietary technologies from third parties that are or may become important or necessary to our ADC platform and/or targeted therapeutics pipeline
10. 43Under our current and future license agreements, we may not have all intellectual property rights necessary for developing, commercializing, and protecting our current or future targeted therapeutics
11. 44Intellectual property rights of third parties could adversely affect our ability to commercialize our targeted therapeutics, and we might be required to obtain licenses from third parties to engage in development or marketing efforts, which may not be available on commercially reasonable terms or at all
12. 45Others may challenge inventorship or claim an ownership interest in our intellectual property which could expose us to litigation and have a significant adverse effect on our prospects
13. 46If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
14. 47We may be subject to claims by third parties that we or our employees or consultants have wrongfully used or disclosed their alleged trade secrets or other proprietary information
15. 48If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
16. 49Intellectual property rights do not necessarily address all potential threats to our business

Risks Related to Our Business Operations and Industry

1. 50Any inability to attract and retain qualified key management, technical personnel and employees would impair our ability to implement our business plan. In addition, prior successes of our personnel may not be indicative of our future success
2. 51In addition, although our leadership team and other key personnel previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, no assurance can be given that their prior successes will be indicative of our future success
3. 52We may experience difficulties in managing our growth and expanding our operations
4. 53Our employees, principal investigators, vendors and commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements

Risks Related to our Common Stock

1. 54An active trading market for our common stock may not be sustained, which may make it difficult for you to sell your shares
2. 55The market price of our common stock is expected to be volatile, and purchasers of our common stock could incur substantial losses
3. 56Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stock
4. 57Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval
5. 58Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall
6. 59We are an “emerging growth company” and our election of reduced reporting requirements applicable to emerging growth companies may make our common stock less attractive to investors
7. 60Our ability to use net operating loss carryforwards and other tax attributes may be limited
8. 61Capital appreciation, if any, will be a stockholder’s sole source of gain
9. 62Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management
10. 63We could be subject to securities class action litigation or stockholder derivative litigation
11. 64Unfavorable global economic and political conditions could adversely affect our business, financial condition or results of operations
12. 65Future changes in financial accounting standards or practices may cause adverse and unexpected revenue fluctuations and adversely affect our reported results of operations
13. 66Changes in tax laws or regulations that are applied adversely to us or our vendors or collaborators may have a material adverse effect on our business, cash flow, financial condition or results of operations
14. 67If we are unable to maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired
15. 68Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
16. 69We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to public company reporting and compliance initiatives
17. 70If securities or industry analysts publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
18. 71If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected